LXEO
Lexeo Therapeutics, Inc. · Healthcare · Market cap $242.9M
Insiders sold $18K net in the last 90 days ·3 sellers, 0 buyers· latest Form 4 filed Nov 18, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$746K
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Latest filing
Nov 18, 2026
Tamayo Louis Edward
Lexeo Therapeutics, Inc. (LXEO) has 25 SEC Form 4 filings (29 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Nov 18, 2026.
Inside the rolling window, 4 insiders at Lexeo Therapeutics, Inc. reported no open-market purchases and 16 open-market sales totaling $746K. The most active filer is Chief Operating Officer Otero Jose Manuel with 6 filings. Insiders have net sold $318K over the trailing 6 months. The most recent open-market filing is a sale of 1,007 shares by Chief Financial Officer Tamayo Louis Edward, dated Nov 17, 2026, worth $3K.
- Industry:Biotechnology
- CEO:R. Nolan Townsend
- Employees:63
- HQ:New York City, NY, US
- IPO:2023-11-03
| Source | |||||||
|---|---|---|---|---|---|---|---|
Tamayo Louis EdwardFirst in 3 months | Chief Financial Officer | Sale | 1,007 | $3K | Nov 18 | +0.3% | SEC ↗ |
Otero Jose ManuelFirst in 3 months | Chief Operating Officer | Sale | 1,285 | $4K | Nov 18 | +0.3% | SEC ↗ |
Townsend Richard NolanFirst in 3 months | Chief Executive Officer | Sale | 3,295 | $11K | Nov 18 | +0.3% | SEC ↗ |
| Chief Executive Officer | Sale | 3,345 | $17K | Aug 19 | -44.9% | SEC ↗ | |
| Chief Operating Officer | Sale | 1,304 | $6K | Aug 19 | -44.9% | SEC ↗ | |
| Chief Financial Officer | Sale | 4,117 | $20K | Aug 19 | -44.9% | SEC ↗ | |
Tamayo Louis EdwardFirst filing | Chief Financial Officer | Sale | 4,641 | $21K | Jul 1 | -33.5% | SEC ↗ |
| Chief Operating Officer | Sale | 4,666 | $21K | Jul 1 | -33.5% | SEC ↗ | |
Bhalla Narinder PalFirst filing | Chief Medical Officer | Sale | 22,306 | $99K | Jul 1 | -33.5% | SEC ↗ |
| Chief Executive Officer | Sale | 25,947 | $116K | Jul 1 | -33.5% | SEC ↗ | |
| Chief Executive Officer | Sale | 3,342 | $17K | May 20 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 1,302 | $7K | May 20 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 55,000 | $313K | Apr 7 | — | SEC ↗ | |
Otero Jose ManuelFirst filing | Chief Operating Officer | Sale | 721 | $7K | Feb 20 | — | SEC ↗ |
Otero Jose ManuelFirst filing | Chief Operating Officer | Sale | 3,016 | $19K | Feb 20 | — | SEC ↗ |
Townsend Richard NolanFirst filing | Chief Executive Officer | Sale | 10,173 | $65K | Feb 20 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does LXEO have?
Lexeo Therapeutics, Inc. (LXEO) has 25 SEC Form 4 filings (29 transaction rows) in the rolling 365-day window, disclosed by 4 distinct insiders. Most recent filing: Nov 18, 2026.
When was the most recent SEC Form 4 filing for LXEO?
The most recent Form 4 filing for LXEO on Tracefour is dated Nov 18, 2026.
Who is the most active insider at LXEO?
The most active SEC Form 4 filer at LXEO in the rolling window is Chief Operating Officer Otero Jose Manuel, with 6 filings.
What is the net insider flow at LXEO over the last 6 months?
Over the trailing 180 days, insiders at LXEO have net sold $318K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at LXEO in the current window?
Inside the rolling window, insiders at LXEO bought $0 and sold $746K based on SEC Form 4 filings.
Can I get alerts for LXEO insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Lexeo Therapeutics, Inc. (LXEO). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Lexeo Therapeutics, Inc. is in the Healthcare sector.